hotspot -WSS

hotspot

author：explore 2025-09-29 01:45:25 - browse：62844

A black and white cutout photo of Feng Zhang on the left of a black and white cutout photo of Alex Aravanis. Both photos are placed on top of yellow geometric shapes and a gradient dark blue background. — Researcher Feng Zhang, left, and Alex Aravanis, the CEO of Moonwalk. Illustration: Christine Kao/STAT; Photo: Katherine Taylor for STAT and Business Wire

A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and Illumina, and others has raised $57 million to develop a defanged form of gene editing that doesn’t cut the DNA strand.

Moonwalk Therapeutics launched Thursday with funding from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, Khosla Ventures, GV, and YK Bioventures. It plans to use that money to develop treatments for a variety of diseases, including chronic and aging-related conditions, using what’s called epigenetic editing.

Most of the gene editing technologies being used today slice or nick the DNA strand and make permanent changes to the biological building blocks of genes. Moonwalk, however, plans to alter the activity of genes by focusing on chemical changes. The company is targeting the surrounding chemicals that influence how genes act. This can be done through chemical processes methylation, which turns genes on, or demethylation, which turns genes off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Can we make enough H5N1 bird flu vaccine if there's a pandemic?

focus

WSS

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

When prostate cancer spreads, where it goes matters

The FDA weighs the risks of candy

Why Sanofi got shellacked over its spinoff

explore

hotspot

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Moonlake's readout produced a cash windfall. Risks remain

Addiction experts warn against a second 'war on drugs'

Apple is now the first public company to be valued at $3 trillion

Diversifying clinical trials isn't enough to close racial gaps: study

Cancer drug shortages should be causing more outrage

Readout Newsletter: XBI biotech index, Akero Therapeutics

ChatGPT in medicine: STAT answers readers' burning questions

The FDA weighs the risks of candy

focus

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Meta's Zuckerberg and Chan on track to put $50 billion into science

Medtronic CEO on promising devices for diabetes, hypertension

Anxious about a speech? A startup wants you to pop a minty cardiac drug

focus

leisure time

hotspot

hotspot